X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SmithKline Beecham Leading the health food drink market - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • May 8, 2000

    SmithKline Beecham Leading the health food drink market

    The malted food drink market in India is divided among the four players Heinz, Cadburys, Nestle and SmithKline Beecham Consumer Healthcare (SBCH). Since the other three are single brand entities at least in the malted drinks categories SBCH has a wider portfolio.

    Acquisition provides good opportunity to grow
    Recently SBCH has acquired the leading brands Viva and Maltova from Jagatjit Industries Ltd. for a consideration of Rs 862.5 m. The two brands will enable SBCH to consolidate its presence in the health food drink segment.

    The malted food drink market in India is estimated to be 90,000 tonnes in volume terms and Rs 9 bn in value terms. Currently Horlicks enjoys the market share of 54% and Boost 10%. Addition of the two brands Viva and Maltova will help the company in increasing its market share to 72% from 64% in the health food drink market. Viva and Maltova are priced at the lower end of the segment, while Horlicks and Boost are present in the upper end of the market. This will give the company a presence in all segments of the market.

    Market share in the health food drink market
    Brand Market Share
    Horlicks 54.0%
    Boost 10.0%
    Maltova & Viva 8.0%
    Bournvita 13.0%
    Complan 12.0%
    Milo 3.0%
    Total 100.0%

    Best Profit margins among the competitors
    SBCH enjoys comparatively better profit margins among its nearest competitors Nestle and Cadbury. Effective cost control measures, and improved realisations have helped the company in maintaining its higher profit margins. Further its zero debt status will also contribute in bettering its profit margins in coming years.

    Comparative profit margins
    Particulars SBCH Nestle Cadbury
    Operating profit margin 16.70% 15.20% 15.20%
    Net profit margin 13.20% 6.90% 7.30%

    Valuations
    At the current market price of Rs 334, SBCH is trading near to its 52 week low with P/E ratio of 15.5 times its FY99 earnings. In the past 2 years, the stock has enjoyed a P/E ratio in the range of 25-40 times. Also compared to its peers, its valuations are the lowest. The company has clearly emerged as a market leader with the strategic acquisition of two brands. Maybe a re-rating of the stock is in the offing.

     

     

    Equitymaster requests your view! Post a comment on "SmithKline Beecham Leading the health food drink market". Click here!

      
     

    More Views on News

    GSK Consumer: On the Recovery Path (Quarterly Results Update - Detailed)

    Jun 20, 2017

    While GSK consumer reported muted revenue growth, volumes are seen to be recovering.

    GSK Consumer: Price Hike Hurts Volumes (Quarterly Results Update - Detailed)

    Nov 30, 2016

    GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.

    GSK Consumer: Slowdown in demand impacts sales (Quarterly Results Update - Detailed)

    Oct 5, 2016

    GSK Consumer Healthcare has announced the first quarter results of the financial year 2016-2017 (1QFY17). The company's sales declined by 1.4% YoY while net profit rose by 2.9% YoY during the quarter.

    GSK Consumer: A Forgetful Year (Quarterly Results Update - Detailed)

    Jun 1, 2016

    GSK Consumer Healthcare announced its results for the quarter and year ended March 2016. During the quarter, sales and profit came in lower by 9% YoY and 8% YoY respectively.

    GSK Consumer: Feeling the Growth Pressures? (Quarterly Results Update - Detailed)

    Feb 15, 2016

    GSK Consumer Healthcare announced its results for the quarter ended December 2015. While revenues were up by 2% YoY, profits were higher by 37% YoY.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK CONSUMER SHARE PRICE


    Aug 21, 2017 10:50 AM

    TRACK GSK CONSUMER

    • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK CONSUMER - COCA COLA COMPARISON

    Compare Company With Charts

    COMPARE GSK CONSUMER WITH

    MARKET STATS